UK Campaign to Stop Genetically Modified Human Embryos
By Marcy Darnovsky,
Genetic Crossroads
| 02. 28. 2007
The UK-based Human Genetics Alert (HGA) has launched a campaign to prevent Britain from becoming the first country in the world to sanction the production of genetically modified human embryos. As reported in the January issue of Genetic Crossroads, a bill set to be introduced would allow British scientists to begin developing technologies that could be used in efforts toward inheritable genetic modification.
Speaking at an HGA press conference, Dr. Richard Nicholson, editor of the Bulletin of Medical Ethics, said, "Every country that has legislated on this subject has banned it. Thus the British Government's decision breaks ranks with the international community, and may lead to the perception that Britain is a haven for irresponsible and profit-driven scientists."
The proposed law maintains the UK's existing ban on creating genetically modified children. But although the white paper supporting the proposed legislation says that genetically altering eggs, sperm and embryos "should not be permitted for reproductive purposes," it adds that this is only "for the foreseeable future, and until such time as safety and efficacy are assured."
HGA Director Dr...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...